Immunitrack is proud to share news of a collaboration with the National Cancer Centre Singapore (NCCS) led by principal investigator Professor Toh Han Chong, Senior Consultant in the Division of Medical Oncology and Deputy Chief Executive Officer of Strategic Partnerships at NCCS.
The phase II trial titled the “Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC” [Clinical Trials.org Identifier: NCT04912765], is one of the largest neoantigen targeting dendritic cell vaccine trials to date.
It will assess the ability of an intra-dermal NA-DC vaccine combined with checkpoint inhibitor nivolumab, as adjuvant treatment for 60 patients with resectable liver cancer or for colorectal cancer patients with liver metastasis (30 from each group). This trial will be conducted in NCCS and is estimated to be completed by May 2025.
Currently, there are no confirmed effective post-surgery adjuvant treatments for patients with resectable liver cancer or colorectal cancer with liver metastasis even though there is risk of relapse within 2 years in approximately 50% of cases. This highlights a strong unmet need for alternative therapies for these patients.
The primary objectives of the clinical trial are to investigate the efficacy in reducing the 2-year post-surgery relapse rates in both cancers, and carry out immunological assessments for neoantigen-specific immune responses after vaccination.
The therapy is developed using NCCS’s in-house autologous dendritic cell vaccine platform and in partnership with a Singaporean start-up biotechnology company and the global biopharmaceutical company Bristol Myers Squibb. The therapy aims to vaccinate patients with gene mutation-derived neoantigen candidates that are selected using the open-source “OpenVax” computational workflow.
Immunitrack's NeoScreen Technology
The range of neo-epitopes selected by NCCS will be assessed by Immunitrack’s proprietary NeoScreen MHC/Peptide Binding Assay, post treatment. This further retrospective analysis will shed light on the stability of the epitopes selected by NCCS, and the correlation with therapeutic efficacy to neoantigen targeting dendritic cell vaccine. This collaboration marks an important milestone for Immunitrack in demonstrating the efficacy of our platform in selecting the right neo-epitopes for personalised cancer vaccination.